DiaSorin S.p.A.: Business Overview, Financials & Competitive Analysis
DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, focusing on the immunodiagnostics and molecular diagnostics segments. The business model is largely based on razor-blade logic: DiaSorin install...
Cyborg Score thesis
Established diagnostics leader with recurring revenue model and next-generation platforms positioned for 2026+ growth, though...
Read the full analyst-debate transcript →Get the Latest DiaSorin S.p.A. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDiaSorin S.p.A. Overview
Pro stress-test →DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, focusing on the immunodiagnostics and molecular diagnostics segments. The business model is largely based on razor-blade logic: DiaSorin installs analyzers in laboratories and then generates recurring revenue through the sale of reagents and test kits that run on those systems.
Strategic Profile
Pro stress-test →Excluding COVID-related sales, the company's core business grew 5% for FY 2025, demonstrating the strength of its specialty diagnostic portfolio. The successful LIAISON PLEX rollout and upcoming LIAISON NES launch position the company to capitalize on the hospital and specialty diagnostics markets.
Competitive Landscape
Pro stress-test →QuidelOrtho, Bio-Rad Laboratories, Sartorius, Revvity, and BioMérieux are among DiaSorin's 13 competitors. DiaSorin differentiates through proprietary analyzer platforms with recurring consumables revenue, particularly in immunodiagnostics and molecular diagnostics segments where it maintains global leadership positioning.
Industry Context
DiaSorin S.p.A. operates in In Vitro Diagnostics & Laboratory Medicine.
Key facts
Founded: 1968 · Headquarters: Saluggia, Italy · Employees: 2,500 · Revenue: $1.35B · Market cap: $3.63B